FDA approves Vivus weight–loss pill Qsymia
Vivus was set to head a pack of three companies vying to get new drugs approved, but the U.S. Food and Drug Administration delayed its decision for three months to review the company's plan for reducing risks once the drug is sold, such as birth …
See all stories on this topic »